Dear Dr. X

I’d like to make you aware of an important trial for patients with unexplained exertional dyspnea who may be suffering from **Heart Failure with Preserved Ejection Fraction (HFpEF**).

Despite recent advancements in medical therapy, HFpEF remains one of the greatest unmet needs in cardiovascular medicine. We are pleased to be able to offer a new investigational therapy to HFpEF patients through our participation in RESPONDER-HF. The **RESPONDER-HF trial is being sponsored by Corvia Medical to confirm the clinical efficacy of the Corvia® Atrial Shunt System in HF patients with elevated left atrial pressure (LAP) and an ejection fraction (EF) over 40%, who remain symptomatic despite Guideline Directed Medical Therapy (GDMT).**

The atrial shunt is placed during a catheter-based procedure to create a small, permanent communication between the left and right atria. This allows blood from the high-pressure left atrium (LA) to exit to the right atrium, reducing the pressure in the LA, the main cause of symptoms, HF admissions and poor quality of life.

As one of the Principal Investigators for the study, my team is available to conduct a full work-up to confirm HFpEF diagnosis in potential study participants as well as to evaluate patients for trial candidacy.

I have attached additional information about previous trial results with the Corvia Atrial Shunt as well as the RESPONDER-HF trial. If you are interested in learning more, or have potential candidates in mind, please feel free to contact me using the information below.

Kind regards,

Dr. XX XXXXX
email@example.com
987-654-3210

<Attach Referring Physician Brochure>